ACE and hereditary angioedema: This dose has been used successfully for the management of ACE inhibitor-induced angioedema and hereditary angioedema {Baş, 2015, A randomized trial of icatibant in ACE-inhibitor-induced angioedema}{Cicardi, 2010, Icatibant’, a new bradykinin-receptor antagonist’, in hereditary angioedema}.